Most interestingly, one patient who underwent ASCT for AML with mutated NPM1 and FLT3-ITD and who had no DTA-CH was diagnosed with AML with an IDH2 mutation 8.5 years later without evidence of either mutated NMP1 or FLT3-ITD or DTA mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.